[A] Agilent: Q4 2026 Earnings Preview on Pharma Instruments and Margins

Agilent Technologies (A) sells analytical instruments, consumables, software and services to pharmaceutical, diagnostics, chemicals and materials, food, environmental and research laboratories, and its fiscal year ends on October 31[1][2]. Ahead of this Agilent Q4 2026 earnings preview, the company has announced that it will report results on 2026-11-23 for its Fourth quarter fiscal 2026 (three months ended October 31, 2026)[3][4]. The latest disclosed quarter is fiscal third quarter 2026, when revenue was $1.88 billion, up 8.1% reported and 7.3% core, GAAP operating margin was 23.6%, and non-GAAP EPS was $1.62, including $0.06 from tariff refunds[5]. In August the company guided fourth-quarter revenue to $1.98 billion to $2.0 billion (5.2% to 6.2% core growth) and non-GAAP EPS to $1.71 to $1.74, and said the guidance includes no future tariff refunds[5]; the Zacks consensus of analyst estimates calls for revenue of $1.99 billion and EPS of $1.72[4].

Three things matter most in this report. The first is whether instrument revenue can grow more than 7% from a prior-year base of about $653 million: third-quarter instrument revenue was $643 million, up 7.3%[2][6], and because the fourth quarter is the company's heaviest instrument quarter, it decides whether the pharma liquid-chromatography replacement cycle can deliver the full-year guidance. The second is whether CrossLab consumables and services can grow more than 6% from a base of about $755 million: third-quarter revenue was $786 million, up 5.6%[7], but second-quarter core growth was only 2%[8], and the split between volume and price is still unclear. The third is whether operating margin is still expanding once tariff refunds are excluded: third-quarter non-GAAP operating margin was 28.3%, with about 110 basis points from refunds[5], and since fourth-quarter guidance excludes refunds, it is the first clean quarter to test whether the expansion can last.

Company Background and Business Structure

Agilent is an instrument and services company built around laboratory analytical workflows, with fiscal 2025 revenue of $6.948 billion[1]. Its customers span many end markets: in fiscal 2025, pharmaceutical and biotechnology revenue was $2.507 billion, chemicals and advanced materials $1.561 billion, diagnostics and clinical $1.029 billion, environmental and forensics $674 million, food $637 million, and academia and government $540 million[2]. Pharma and biotech account for about 36% of company revenue and are the main source of its most cycle-sensitive instrument demand.

The company reorganized into three segments in the first quarter of fiscal 2025[9]. Life Sciences and Diagnostics Markets (LDG) had fiscal 2025 revenue of $2.726 billion and segment operating income of $536 million[1], covering liquid chromatography and LC-MS instruments, pathology diagnostics and Advanced Therapeutics contract manufacturing[10][11]; Agilent CrossLab (ACG) had revenue of $2.908 billion and segment operating income of $946 million[1], selling chromatography consumables and providing repair, compliance and enterprise services[12]. Applied Markets (AMG) had revenue of $1.314 billion and segment operating income of $301 million[1], covering atomic spectroscopy, vacuum pumps and remarketed instruments, with vacuum products used in semiconductor, battery, chemical and advanced-materials industries[9][10]; management said new products such as the 9500 ICP-MS are tracking ahead of plan, with order funnels above $60 million[10].

The mix of instrument and non-instrument revenue sets how volatile Agilent's revenue is. In fiscal 2025, instrument revenue was $2.427 billion and non-instrument revenue from consumables, services and other was $4.521 billion[2], and the latter follows customers' daily testing volumes and is far steadier than instruments. By region, fiscal 2025 revenue was $2.806 billion in the Americas, $1.923 billion in Europe and $2.219 billion in Asia Pacific[2].

The June 2026 Biocare acquisition changed both LDG's composition and the balance sheet. On June 24, 2026, Agilent acquired Biocare for net consideration of $950 million and placed it in LDG to broaden its pathology portfolio, recording $549 million of goodwill and $520 million of other intangible assets[11]. The day after closing, the company issued $600 million of senior notes due 2032[11].

Financial History and Current Position

Agilent's revenue recovered in fiscal 2025 after the fiscal 2024 decline, but segment profit has not yet returned to the fiscal 2023 level. Revenue was $6.833 billion in fiscal 2023, $6.510 billion in fiscal 2024 (down 4.7%) and $6.948 billion in fiscal 2025 (up 6.7%), while total segment operating income was $1.875 billion, $1.721 billion and $1.783 billion[1]. Fiscal 2025 GAAP operating income was $1.479 billion and net income was $1.303 billion[13].

Instrument revenue was the most volatile line in this cycle. It fell from $2.742 billion in fiscal 2023 to $2.354 billion in fiscal 2024, a drop of about 14%, and recovered to $2.427 billion in fiscal 2025; over the same years non-instrument revenue rose from $4.091 billion to $4.156 billion and $4.521 billion[2]. That means almost all of the fiscal 2024 revenue decline came from instruments.

Operating cash flow in fiscal 2025 was lower than in the two prior years, and capital returns shrank sharply. Operating cash flow was $1.772 billion in fiscal 2023, $1.751 billion in fiscal 2024 and $1.559 billion in fiscal 2025; in fiscal 2025 capital spending was $407 million, buybacks $425 million and dividends $282 million, compared with buybacks of $1.150 billion in fiscal 2024[13]. Cash, cash equivalents and restricted cash were $1.791 billion at the end of fiscal 2025[13].

Revenue growth has stepped up through fiscal 2026, and margin rose clearly in the third quarter. In the second quarter (ended April 30), revenue was $1.83 billion, up 10.0% reported and 6.3% core, with a 26.4% non-GAAP operating margin[14]; in the third quarter (ended July 31), revenue was $1.878 billion, GAAP operating income $444 million, net income $362 million and EPS $1.28[15][5]. Nine-month revenue was $5.511 billion, up 8.3% from $5.087 billion a year earlier[7].

Cash in the first nine months went mainly to acquisitions, and debt rose as a result. Nine-month operating cash flow in fiscal 2026 was $1.064 billion, only $50 million more than a year earlier, while capital spending was $249 million, acquisitions $950 million, buybacks $295 million and dividends $216 million[15]. At July 31, 2026, short-term debt was $304 million and long-term debt $3.645 billion, a total of $3.949 billion versus $3.354 billion at the end of fiscal 2025, and cash and restricted cash stood at $1.760 billion[11][15].

The company updated its full-year outlook in the third quarter and raised its margin-expansion target. Fiscal 2026 revenue guidance is $7.49 billion to $7.51 billion (up 7.8% to 8.1% reported and 5.8% to 6.0% core), non-GAAP EPS $6.18 to $6.21, and non-GAAP operating margin expansion of more than 130 basis points at the midpoint of core growth, including about 30 basis points from third-quarter refunds[5]; on the call, management framed the ex-refund expansion target as more than 100 basis points[16]. On the second-quarter call, management kept full-year operating cash flow guidance at $1.6 billion to $1.7 billion and cut capital spending guidance by $50 million to about $450 million[8].

Operating Model

Agilent's revenue is easiest to understand as two parts: instruments and non-instruments. Instrument revenue is roughly the number of units customers buy to replace or build labs times the unit price, and it is customer capital spending; consumables and services revenue is roughly the installed base times usage per unit and service contract pricing, and the two lines were $2.427 billion and $4.521 billion in fiscal 2025[2]. In fiscal 2026, management said net pricing contributed about 200 basis points to revenue growth[8][10], and Biocare has added non-core revenue since June 24[11].

Instrument orders turn into revenue with a lag of one to two quarters, while new installations pull through consumables and services for years afterward. Pharma customers' equipment upgrades first appear as LC and LC-MS instrument orders and are then recognized as LDG instrument revenue in later quarters; management said that as of the second quarter, the instrument book-to-bill ratio had been above 1 for 9 consecutive quarters[8]. The pharma reshoring orders won in the third quarter will only begin to produce revenue in fiscal 2027, and management said instrument and service revenue from reshoring is entirely incremental, while consumables may see some substitution[16].

Margin depends on price, product mix, labor costs, tariffs and amortization. In fiscal 2025, total segment operating income was $1.783 billion, a margin of about 25.7%, made up of ACG at $946 million (32.5%), LDG at $536 million (19.7%) and AMG at $301 million (22.9%)[1]; GAAP operating income, which also deducts intangible amortization and transformation and integration costs, was $1.479 billion (21.3%)[13]. The fourth quarter is usually the highest-margin quarter, and on the second-quarter call management said margin would expand about 220 basis points from the third to the fourth quarter in line with historical seasonality[8]; the derived fiscal 2025 fourth-quarter segment margin was 27.1%[1][7].

Operating cash flow is roughly net income plus non-cash charges, less working-capital investment. In the first nine months of fiscal 2026, net income was $1.006 billion, $137 million more than a year earlier, but inventory absorbed $110 million and other assets and liabilities drained $295 million, versus $72 million and $61 million a year earlier[15], so profit growth did not turn into a matching rise in cash. Cash goes mainly to capital spending (about $450 million guided for the year[8]), acquisitions, buybacks and dividends, and the company disclosed future intangible amortization of about $27 million per quarter[5].

Industry and Competitive Position

Agilent is one of the world's main suppliers of analytical instruments and laboratory services, with liquid and gas chromatography as its traditional strengths. Management said second-quarter LC, LC-MS and GC instrument revenue each grew low double digits, driven by the replacement cycle and share gains from new products[8]; on the first-quarter call it said Infinity-series HPLC was growing high single digits and gaining share globally[12]. Around that installed base, ACG keeps selling consumables and services, and enterprise services are about 10% of services revenue[12].

Agilent competes with Thermo Fisher, Waters, Shimadzu and Danaher businesses in instruments, and with diagnostics companies in pathology. The available material covers only Agilent's own disclosures and lacks competitors' revenue or share data for the same periods, so it cannot show directly whether Agilent is gaining share in this replacement cycle. Management's share-gain claims remain the company's own statements for now.

Industry demand fell in 2023-2024 as customers cut capital spending and recovered in 2025-2026 with the instrument replacement cycle. Agilent's revenue fell 4.7% in fiscal 2024 and rose 6.7% in fiscal 2025[1]; the main constraints are customer capital budgets, academic research funding, swings in China demand and tariffs. China revenue growth was +6% in the first quarter of fiscal 2026, −9% in the second and +9% in the third[12][8][10], and management said third-quarter China growth came mainly from pharma and food demand, with minimal help from stimulus[10].

Core Debates

Can pharma's liquid-chromatography replacement cycle carry Agilent through its peak fourth-quarter buying season?

This debate decides whether the fourth-quarter instrument season can deliver the full-year growth guidance. LDG had fiscal 2025 revenue of $2.726 billion[1], and pharma and biotech is the largest end market, with fiscal 2025 revenue of $2.507 billion, or 36% of the company[2]. Instruments are customer capital spending and swing far more than consumables: company-wide instrument revenue fell from $2.742 billion in fiscal 2023 to $2.354 billion in fiscal 2024 and recovered to $2.427 billion in fiscal 2025, and last year's fourth-quarter instrument revenue of about $653 million was the highest quarter of the year[2][6].

Third-quarter data show pharma demand still accelerating. In fiscal third quarter 2026, pharma end-market revenue was $707 million, up 12.4%, and instrument revenue was $643 million, up 7.3%[6]; LDG revenue was $746 million, up 11.3% (10% core), and segment margin rose to 23.6% from 17.6% a year earlier[7][17]. Management said LC revenue grew low double digits, GLP-1-related revenue grew more than 70% year over year, and orders came from five of the top 10 global pharma companies for reshoring[10], but revenue from those orders will only begin in fiscal 2027[16].

The financial transmission runs from pharma customers' upgrades and capacity additions, to instrument orders, to instrument revenue and LDG profit one to two quarters later. The fourth-quarter comparison bases are instrument revenue of about $653 million, pharma end-market revenue of about $690 million, LDG revenue of about $755 million and an LDG segment margin of about 22.8%, all derived by subtracting the prior-year nine-month comparatives from the fiscal 2025 10-K full-year figures[2][1][6][7]. New installations then bring ACG consumables and services revenue for years.

An alternative reading holds that 2026 growth comes mainly from price, consolidation and an easy base rather than an accelerating volume cycle. Management said net pricing added about 200 basis points in each of the second and third quarters[8][10]; Biocare has been consolidated since June 24[11], and reported and core fourth-quarter growth guidance differ by 1.2 percentage points (including currency)[5]; fiscal 2024 instrument revenue was about 14% below fiscal 2023, leaving a low base[2]. Stripping these out, volume growth may be only mid-single digits, and reshoring orders that only turn into revenue in fiscal 2027 cannot support the fourth quarter.

Four signals in the fourth quarter are worth tracking, and the falsifying conditions are clear. The signals are whether instrument revenue grows more than 7% on the $653 million base, whether pharma end-market growth holds above 9%, whether LDG core growth excluding Biocare stays in the mid-to-high single digits, and whether management keeps reporting an instrument book-to-bill above 1 and quantifies reshoring orders. If instrument revenue falls year over year, volume growth is below 3%, or reshoring revenue slips beyond fiscal 2027, the replacement cycle will have stalled in its peak season and growth will rest mainly on pricing and consolidation.

Is CrossLab's consumables and services growth real volume, or mostly price?

ACG is Agilent's most profit-dense segment, and its growth directly sets company-wide margin. In fiscal 2025, ACG revenue was $2.908 billion, 41.9% of the company, and segment operating income was $946 million, more than half of total segment operating income of $1.783 billion[1]. Its revenue follows customers' daily testing volumes, is steadier than instruments and forms the core of Agilent's recurring revenue.

ACG re-accelerated in the third quarter, but the second-quarter slowdown shows this line is not free of swings. Third-quarter ACG revenue was $786 million, up 5.6% (about 5% core), with a 34.4% segment margin versus 33.3% a year earlier[7][17]; the 10-Q said pharma and chemicals and advanced materials grew fastest, pharma growth came from repair, compliance services and consumables, and academia and government declined because of repair and compliance services[18]. Second-quarter ACG core growth was only 2%, which management attributed to Lunar New Year timing and a tough comparison against pre-tariff stocking in China a year earlier, with growth outside China at the high end of mid-single digits and consumables growing high single digits[8].

The financial transmission runs from customers' lab testing volumes, to consumption of columns and consumables and repair and compliance contracts, to ACG revenue and profit. The fourth-quarter comparison bases are ACG revenue of about $755 million, a segment margin of about 32.6%, company-wide non-instrument revenue of about $1.208 billion and academia and government revenue of about $136 million[1][2][7][6]. In the third quarter, company-wide non-instrument revenue was $1.235 billion, up 8.4%, and academia and government revenue was $128 million, down 3.0%[6].

An alternative reading holds that part of the third-quarter rebound reflects China catch-up orders and pricing rather than real volume growth. China revenue fell 9% in the second quarter and rose 9% in the third[8][10], on top of about 200 basis points of net pricing[10]; if China goes flat again in the fourth quarter, ACG's underlying volume growth may be only low single digits. Shrinking repair contracts with academic and government customers would also slow this line[18].

In the fourth quarter, the first question is whether ACG grows more than 6% on the $755 million base and whether segment margin beats last year's 32.6%. Whether China stays positive and delivers management's raised full-year mid-single-digit growth[16], and whether academia and government stops declining, matter just as much. If ACG growth drops below 3%, China turns negative in the fourth quarter, or tighter research funding causes repair contracts to lapse, pricing will have masked stagnant usage and the third-quarter rebound will have been catch-up ordering.

Excluding tariff refunds, is Agilent's operating margin still expanding?

This debate concerns whether Agilent can deliver its main operating commitment for fiscal 2026. From fiscal 2023 to fiscal 2025, revenue returned from $6.833 billion to $6.948 billion, but total segment operating income fell from $1.875 billion to $1.783 billion[1]. Management made margin expansion its main commitment for fiscal 2026, the third-quarter expansion included one-time tariff refunds, and fourth-quarter guidance excludes refunds[5], so the fourth quarter is the first clean quarter for judging whether the expansion can last.

Margin still expanded in the third quarter after excluding refunds, but the improvement came mainly from price. Third-quarter non-GAAP operating margin was 28.3%, with about 110 basis points from refunds, leaving about 27.2%, still about 210 basis points higher than a year earlier[5]. The 10-Q said gross margin rose 4 percentage points in the quarter because of volume, tariff refunds, targeted price increases, business mix and lower amortization and restructuring costs, while selling, general and administrative expense rose 14%, mainly from transformation initiatives, variable pay and wage increases[19]; management said net pricing added about 200 basis points in each of the second and third quarters[8][10].

The financial transmission is that pricing and procurement savings lift gross margin, wages, variable pay, transformation costs and Biocare amortization offset part of the gain, and profit, after working-capital changes, becomes operating cash flow. The fourth-quarter comparison bases are a total segment operating margin of about 27.1% (close to the non-GAAP measure), a GAAP operating margin of about 23.8% and operating cash flow of about $545 million[1][13][7][15]; the third-quarter net benefit from tariff refunds was $17 million, or $0.06 per share[5]. Nine-month operating cash flow was $1.064 billion, only $50 million more than a year earlier[15].

An alternative reading holds that margin expansion comes mainly from pricing, which is hard to sustain when customer budgets tighten. On that view, most of the third-quarter expansion came from refunds, mix and an easier prior-year base, and ex-refund expansion will narrow clearly in the fourth quarter; amortization and transformation costs tied to Biocare would also squeeze the room, and the company disclosed future intangible amortization of about $27 million per quarter[5]. In February 2026 the U.S. Supreme Court invalidated certain IEEPA tariffs, and the related refunds remain subject to potential appeal[20], which makes the refunds themselves uncertain.

In the fourth quarter, the test is whether ex-refund segment operating margin reaches 28.5% or more and whether management's disclosed pricing contribution holds at about 200 basis points. Investors will also need to see whether any further tariff refund is recognized and shown separately, and whether quarterly operating cash flow exceeds $600 million. If ex-refund margin is flat year over year, pricing contribution falls while volume growth cannot cover wage and amortization increases, or profit growth fails to turn into cash and full-year operating cash flow lands below the $1.6 billion to $1.7 billion guidance[8], the expansion will prove to have been a one-time gain.

Risks and Falsifiers

The acquisition and balance-sheet risk comes from the debt and intangible assets added by the Biocare deal. Agilent paid $950 million for Biocare in June 2026, recorded $549 million of goodwill and $520 million of intangible assets, and issued $600 million of notes due 2032 at the same time[11]; total debt at the end of July was $3.949 billion, up from $3.354 billion at the end of fiscal 2025, with cash and restricted cash of $1.760 billion[11][15]. A troubled integration would raise goodwill impairment risk and hit GAAP operating income directly; if Biocare contributes revenue as planned in the fourth quarter, LDG segment margin is no lower than a year earlier and the company takes on no large new borrowing, this concern weakens.

The risk in Advanced Therapeutics contract manufacturing lies in customers' filing timing and depreciation on new capacity. Management said the business grew nearly 30% in the third quarter[10], but expects flattish fourth-quarter growth because of the timing of customers' regulatory submissions; the new Train C capacity reached mechanical completion in the second quarter, is scheduled for commercial go-live in spring 2027 and will ramp over the next 6 to 8 quarters, with most capacity already booked[8][16]. Pre-revenue depreciation will weigh on margin, and further filing delays would also drag on LDG growth and non-instrument revenue; if the business grows at least flat in the fourth quarter and Train C goes live on schedule, this risk is falsified.

The instrument replacement cycle could peak in 2027. After pharma customers concentrated their LC replacements in 2025-2026, purchases may fall back, and reshoring orders can only partly fill the gap; based on fiscal 2025 instrument revenue of $2.427 billion, each 1% change in instrument revenue moves full-year revenue by about $24 million[2], with the biggest effect in the peak fourth quarter. If fourth-quarter instrument revenue grows at least 7% and book-to-bill stays above 1, this concern does not hold for now.

Swings in China and academic research demand hit ACG revenue directly. China's quarterly growth has swung between −9% and +9%[8][10], and the academia and government end market, with fiscal 2025 revenue of $540 million, was still declining in the third quarter of fiscal 2026[2][6]; every 5% decline in that end market removes about $27 million of revenue. If China grows year over year and academia and government is flat or up in the fourth quarter, this risk is falsified.

Whether pricing can last determines the quality of the margin expansion. The expansion depends on about 200 basis points of net pricing[10] while wages, variable pay, transformation costs and Biocare amortization are all rising, and third-quarter SG&A grew 14% year over year[19]; at full-year revenue of about $7.5 billion[5], 100 basis points of pricing equals about $75 million of revenue and nearly as much operating profit. If fourth-quarter ex-refund segment operating margin expands by at least about 140 basis points year over year, this concern weakens.

Tariff policy reversals could unwind refund gains already booked. On February 20, 2026, the U.S. Supreme Court invalidated certain tariffs imposed under IEEPA and the Court of International Trade then ordered refunds, subject to potential appeal[20]; third-quarter refunds added $17 million of non-GAAP net income, or $0.06 per share[5]. If refunds must be reversed or new tariffs are imposed, the impact flows straight into product costs; if no refund is reversed in the fourth quarter and the company says incremental tariff costs are fully offset, this risk is falsified.

What to Watch Next

• Pharma instrument cycle: fourth-quarter instrument revenue against a prior-year base of about $653 million (third quarter $643 million, up 7.3%); growth above 7% confirms the cycle, while a year-over-year decline falsifies it.
• Pharma end market: revenue against a base of about $690 million (third quarter up 12.4%); growth should hold above 9%, and volume growth below 3% would weaken the case.
• LDG: revenue and margin against about $755 million and 22.8% (third quarter 23.6%); core growth excluding Biocare in the mid-to-high single digits confirms the cycle.
• Orders: book-to-bill has been above 1 for 9 straight quarters through the second quarter; reshoring revenue slipping beyond fiscal 2027 would weaken the case.
• CrossLab volume: ACG revenue and margin against about $755 million and 32.6%; growth above 6% with higher margin confirms, and growth below 3% falsifies.
• China and academia: China grew 9% in the third quarter and academia and government had a base of about $136 million; China turning negative falsifies the rebound.
• Ex-refund margin: total segment operating margin against about 27.1% a year earlier; 28.5% or more confirms, flat year over year falsifies.
• Pricing and refunds: about 200 basis points of pricing and a $17 million third-quarter refund; falling pricing with insufficient volume falsifies, and any refund should be shown separately.
• Cash flow: fourth-quarter operating cash flow against about $545 million a year earlier; above $600 million confirms, and a full year below the $1.6 billion to $1.7 billion guidance falsifies.

Conclusion

Agilent's business runs on two engines: instrument upgrades by pharma and other customers set revenue upside, and CrossLab consumables and services set the profit floor. In fiscal third quarter 2026, revenue was $1.878 billion with 7.3% core growth and an ex-refund non-GAAP operating margin of about 27.2%[5], but nine-month operating cash flow was only $50 million higher than a year earlier, and debt rose to $3.949 billion after the Biocare deal[15][11]. The central unresolved relationship is how much of the growth and margin expansion comes from volume and efficiency, and how much from about 200 basis points of pricing, consolidation and one-time refunds.

Between the August 26, 2026 release of third-quarter results and November 12, the third-party material available was mostly recaps of the results, brokers' adjustments to their views of the stock or automatically generated summaries, and no analysis with specific, independent reasoning could be identified. No outside view is therefore cited here, and the article does not treat that material as a market consensus; the three debates above can only be tested against the company's own disclosures once fourth-quarter results arrive.

If fourth-quarter instrument revenue grows more than 7%, book-to-bill stays above 1, ACG grows more than 6% with China still positive, ex-refund segment margin reaches 28.5% or more and quarterly operating cash flow exceeds $600 million, the view that the replacement cycle and recurring revenue are jointly driving margin expansion would be strengthened. Conversely, if instrument revenue falls year over year, ACG growth drops below 3%, ex-refund margin is flat year over year, or cash flow keeps lagging profit, the 2026 improvement would look more like the product of pricing, consolidation and one-time items.

Sources

[1] A 10-K filed 2025-12-22 · 2025-12-22 · 10-K · https://www.sec.gov/Archives/edgar/data/1090872/000109087225000087/

[2] A 10-K filed 2025-12-22 end markets and revenue type · 2025-12-22 · 10-K · https://www.sec.gov/Archives/edgar/data/1090872/000109087225000087/

[3] Agilent announcement 2026-10-29 Q4 FY2026 results date · 2026-10-29 · Agilent announcement

[4] Zacks Q4 FY2026 preview accessed 2026-11-11 · 2026-11-11 · Zacks(汇总分析师预期) · https://www.tradingview.com/news/zacks:f95ef7527094b:0-agilent-technologies-q4-earnings-on-deck-what-s-in-store-for-the-stock/

[5] A 8-K filed 2026-08-26 Q3 2026 results · 2026-08-26 · 8-K · https://www.sec.gov/Archives/edgar/data/0001090872/000109087226000062/exhibit991-q326pressrelease.htm

[6] A 10-Q filed 2026-09-01 end markets and revenue type · 2026-09-01 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001090872&type=10-Q

[7] A 10-Q filed 2026-09-01 segment results · 2026-09-01 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001090872&type=10-Q

[8] A Q2 2026 earnings call 2026-05-27 · 2026-05-27 · earnings-call

[9] A 10-K filed 2025-12-22 segment organization · 2025-12-22 · 10-K · https://www.sec.gov/Archives/edgar/data/1090872/000109087225000087/

[10] A Q3 2026 earnings call 2026-08-26 · 2026-08-26 · earnings-call

[11] A 10-Q filed 2026-09-01 Biocare acquisition and debt · 2026-09-01 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001090872&type=10-Q

[12] A Q1 2026 earnings call 2026-02-25 · 2026-02-25 · earnings-call

[13] A 10-K filed 2025-12-22 cash flow · 2025-12-22 · 10-K · https://www.sec.gov/Archives/edgar/data/1090872/000109087225000087/

[14] A 8-K filed 2026-05-27 Q2 2026 results · 2026-05-27 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001090872&type=8-K

[15] A 8-K filed 2026-08-26 Q3 2026 statements · 2026-08-26 · 8-K · https://www.sec.gov/Archives/edgar/data/0001090872/000109087226000062/exhibit991-q326pressrelease.htm

[16] A Q3 2026 earnings call 2026-08-26 guidance and Q&A · 2026-08-26 · earnings-call

[17] A 8-K filed 2026-08-26 Q3 2026 segment highlights · 2026-08-26 · 8-K · https://www.sec.gov/Archives/edgar/data/0001090872/000109087226000062/exhibit991-q326pressrelease.htm

[18] A 10-Q filed 2026-09-01 segment revenue drivers · 2026-09-01 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001090872&type=10-Q

[19] A 10-Q filed 2026-09-01 operating results · 2026-09-01 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001090872&type=10-Q

[20] A 10-Q filed 2026-06-01 tariffs · 2026-06-01 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001090872&type=10-Q